Pantec Biosolutions AG   Report issue

For profit Phase 1
Founded: Ruggell Liechtenstein (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2016
NCT02999776
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

calcipotriene (dovonex) (1 trial)

etanercept (enbrel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2